<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The medical treatment of patients with symptomatic intracranial atherosclerotic disease (ICAD) is directed toward reducing the risk of new ischemic events </plain></SENT>
<SENT sid="1" pm="."><plain>The overall strategy is divided into: (1) prevention of occurrence of intraluminal <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, with or without embolism; (2) plaque stabilization and regression; and (3) management of atherogenic risk factors </plain></SENT>
<SENT sid="2" pm="."><plain>In patients with ICAD, short-term and long-term anticoagulation (compared with aspirin) has not shown to be beneficial </plain></SENT>
<SENT sid="3" pm="."><plain>The current guidelines recommend that aspirin monotherapy, the combination of aspirin and extended release <z:chebi fb="0" ids="4653">dipyridamole</z:chebi>, and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> monotherapy (rather than oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>) are <z:hpo ids='HP_0000001'>all</z:hpo> acceptable options in patients with noncardioembolic <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The findings of another pilot trial suggest that symptomatic ICAD is a dynamic lesion and cilostazol may prevent its progression </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, the subgroup analysis from randomized trials, provide evidence about benefit of aggressive atherogenic risk factor management among patients with ICAD </plain></SENT>
<SENT sid="6" pm="."><plain>Current guidelines recommend <z:chebi fb="0" ids="35664">statin</z:chebi> therapy with intensive <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering effects for patients with atherosclerotic <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> with or without known <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> to reduce the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and cardiovascular events </plain></SENT>
</text></document>